H. Lundbeck A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 5.6K
- Market Cap
- -
- Website
- http://www.lundbeck.com
Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 16
- Registration Number
- NCT02340195
- Locations
- 🇩🇪
DE801, Munchen, Germany
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 22
- Registration Number
- NCT02333487
- Locations
- 🇺🇸
US802, Rockville, Maryland, United States
Investigating the Effect of Vortioxetine in Adult ADHD Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 227
- Registration Number
- NCT02327013
- Locations
- 🇺🇸
US016, Las Vegas, Nevada, United States
🇺🇸US015, Beverly Hills, California, United States
🇺🇸US004, National City, California, United States
Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 152
- Registration Number
- NCT02279966
- Locations
- 🇫🇮
FI003, Helsinki, Finland
🇱🇹LT005, Vilnius, Lithuania
🇪🇪EE001, Tallinn, Estonia
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 151
- Registration Number
- NCT02279953
- Locations
- 🇪🇪
EE002, Tallinn, Estonia
🇷🇸RS002, Belgrade, Serbia
🇫🇮FI002, Helsinki, Finland
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 101
- Registration Number
- NCT02272517
- Locations
- 🇫🇮
FI001, Kuopio, Finland
🇫🇮FI006, Kupio, Finland
🇫🇮FI007, Tampere, Finland
Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 28
- Registration Number
- NCT02260830
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 24
- Registration Number
- NCT02231450
- Locations
- 🇩🇪
APEX GmbH, Munich, Germany
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 47
- Registration Number
- NCT02202213
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 96
- Registration Number
- NCT02202226
- Locations
- 🇺🇸
PAREXEL Phase I Unit, Glendale, California, United States
© Copyright 2024. All Rights Reserved by MedPath